The Chinese phase III clinical trial of smeglutide for weight loss has been completed or will soon be declared for marketing in China

Recently, according to the drug clinical trial registration and information publicity platform, Novo Nordsmeglutide injection as an indication for "low-calorie diet and increased physical activity adjuvant therapy for initial body mass index (BMI) ≥ 30 kg/m2 (obesity), or ≥ 27 kg/m2 and < 30 kg/m2 (overweight) and accompanied by at least one comorbidities associated with overweight" The indication phase III clinical trial has been completed.

Obesity has become a global disease, excessive obesity can increase the incidence of type II diabetes, but also induce three highs, cirrhosis and other chronic diseases, seriously shorten life expectancy

Smeglutide Injection is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that requires only subcutaneous administration

It is precisely because of the brilliant weight reduction effect that Smeglutide injection has achieved a very eye-catching sales performance

According to the drug clinical trial registration and information publicity platform, the phase III clinical trial of weight loss carried out by smeglutide injection in China is a randomized, double-blind, international multicenter phase III clinical trial to evaluate the efficacy and safety

As for the final results of the clinical study, no more detailed data has been disclosed

It is also worth noting that in the field of GLP-1 receptor agonist weight loss, the marketing authorization application for liraglutide injection for obesity or overweight indications submitted by Huadong Pharmaceutical's wholly-owned subsidiary of Huadong Pharmaceutical has been accepted by the State Food and Drug Administration, and there are still no domestic enterprises that have declared liraglutide obesity indications